India, Aug. 15 -- An experimental vaccine, ELI-002 2P, has shown encouraging results in preventing the recurrence of pancreatic and colorectal cancers two of the deadliest and most treatment-resistant malignancies.
The therapy targets mutations in the KRAS gene, present in roughly 90 percent of pancreatic and 50 percent of colorectal cancers, and is designed as an "off-the-shelf" treatment that does not require patient-specific customization.
In a Phase 1 clinical trial involving 25 patients who had undergone standard treatments but remained at high risk of relapse, the vaccine triggered strong immune responses in 84 percent of participants. Nearly one-quarter experienced complete clearance of detectable tumor traces.
Median relapse-free...